Dolutegravir + Emtricitabine + Tenofovir Alafenamide
Composition
The formulation contains Tenofovir Alafenamide 25 mg + Emtricitabine 200mg + Dolutegravir 40mg Tablet: Contains tenofovir alafenamide 25mg, emtricitabine 200mg, and dolutegravir 40mg as the active ingredients.
Indications
HIV-1 infection treatment
Side effects
Insomnia, headache, gastrointestinal symptoms
Precautions
Monitor for renal function and risk of opportunistic infections
Contraindications
Co-administration with dofetilide, rifampin, Hypersensitivity to any component of the product
Dosage and administration
One tablet daily
Countries
USA, UK, Australia
Available Forms
Tablets